ID: MRFR/MED/5029-HCR | 100 Pages | Published By Kinjoll Dey on April 2023
The global wearable injectors market is projected to reach USD 21.98 billion by 2030 at a CAGR of 15.2%.
Wearable Injectors Market Overview The wearable injectors market can expect to reach USD 21.98 billion at 15.2% CAGR from 2022-2030, believes Market Research Future (MRFR). The shift in healthcare delivery toward homecare as a result of COVID-19, the advantages of wearable injectors in the administration of various drugs, the rising prevalence of chronic diseases (such as cancer, diabetes, and CVD), favorable reimbursement scenarios in major markets, and technological advancements in injector devices are all driving growth in this market. The COVID-19 pandemic's uncertainty has influenced the demand for various therapeutics and wearable drug delivery technologies. Healthcare systems around the world took steps to postpone treatments for diseases like cancer to prevent the spread of the infection and safeguard high-risk patients from infection. The hazards for individuals receiving care rose as the pandemic began. Hospitals, which serve the bulk of patients, also became high-risk areas during the epidemic. To address these issues and provide appropriate care to patients suffering from various ailments, a movement from hospital-based care to home-based care has occurred. The rising frequency of chronic diseases, technology breakthroughs, design development, increased concern about the dangers of needlestick injuries, and the restrictions on drug delivery with a simple syringe are all factors driving market expansion.
The wearable injectors market has been segmented into type, usage, mechanism of action, therapeutic area, and end-user.
The wearable injectors market, on the basis of type, has been segmented into on-body wearable injectors, off-body wearable injectors, and hand-held wearable injectors.
The wearable injectors market, by usage, has been segmented into disposable and semi-reusable.
The market, by mechanism of action, has been segmented into spring based, motor driven, rotary pump, expanding battery, pressurized gas, and collapsible reservoir.
The market, by therapeutic area, has been segmented into oncology, infectious diseases, cardiovascular diseases, autoimmune diseases, diabetes, and others.
The market, by end-user, has been segmented into hospitals, clinics, homecare, ambulatory surgery centers, others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The wearable injectors market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European wearable injectors market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The wearable injectors market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The wearable injectors market in the Middle East & Africa has been segmented into the Middle East and Africa.
West Pharmaceutical Services, Inc., Valeritas, Inc., Eli Lilly and Company, YPSOMED, Amgen Inc., Becton, Dickinson and Company (BD), CeQur SA, SteadyMed Therapeutics, Inc., BioSpace, Enable Injections, and Sensile Medical AG are some of the key players in the wearable injectors market.
Regional Market Summary
Wearable Injectors Market Share (%), by Region, 2017
Source: World Health Organization (WHO), Centers for Disease Control and Prevention (CDC)
Geographically, the Americas is anticipated to dominate the wearable injectors market owing to a well-developed healthcare sector, rising prevalence of autoimmune and chronic disease and growing healthcare expenditure. According to a report published by American Autoimmune Related Diseases Association (AARDA) in April 2017, in the US approximately 50 million people i.e. nearly 20% population suffer from autoimmune diseases. Additionally, government funding in this region contributes to the growth of the market.
Europe is expected to hold the second largest position in the wearable injectors market. The market growth in this region is attributed to the growing prevalence of chronic diseases, the availability of funds for research, and increasing healthcare expenditure. According to a report published by the NSD Alliance in July 2017, 1/3rd of the European population above the age of 15 years suffer from a chronic disease.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, rising prevalence of chronic diseases like diabetes, cardiovascular diseases and increasing government funding for the healthcare sector. According to a study published in the Asian Pacific Journal of Tropical Biomedicine journal in 2014, it was estimated that about 150 million diabetic patients reside within the region, out of which more than 95% have type 2 diabetes mellitus.
On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.Recent Development
Wearable Injectors Market, by Type
Wearable Injectors Market, by Usage
Wearable Injectors Market, by Mechanism of Action
Wearable Injectors Market, by Therapeutic Area
Wearable Injectors Market, by End User
Wearable Injectors Market, by Region
|Market Size||USD 21.98 billion: 2030|
|Forecast Units||Value (USD Billion)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Type, Usage, Mechanism of action, Therapeutic Area, and End-user|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||West Pharmaceutical Services, Inc., Valeritas, Inc., Eli Lilly and Company, YPSOMED, Amgen Inc., Becton, Dickinson and Company (BD), CeQur SA, SteadyMed Therapeutics, Inc., BioSpace, Enable Injections, and Sensile Medical AG|
|Key Market Opportunities||
|Key Market Drivers||
Wearable Injectors are medical devices designed to dispense large doses of the drug. Wearable Injectors are user-friendly, convenient and they lessen the need for multiple painful injections.
West Pharmaceutical Services, Valeritas, Inc., Eli Lilly and Company, YPSOMED, Amgen Inc., Becton, Dickinson and Company (BD), CeQur SA, SteadyMed Therapeutics, Inc., BioSpace, Enable Injections, and Sensile Medical AG
Global market for the Wearable Injectors would record grow USD 21.98 billion during the forecast period covering 2022-2030.
Factors like convenient methods of drug administration, increasing chronic diseases such as diabetes, better inclusion of advanced technologies, and improved design development in wearable injectors can trigger growth for the Wearable Injectors Market.
Strict government measures and growing resurfacing of traditional methods can hold back the Wearable Injectors Market growth.
Oncology, infectious diseases, cardiovascular diseases, autoimmune diseases, diabetes, and others are the therapeutic areas for the global Wearable Injectors Market.
Americas is the regional Wearable Injectors Market with the maximum market share.
Wearable injectors are used to subcutaneously administer insulin and other drugs that require large dose volumes and extended delivery period.